ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method
Journal Title: Turkish Journal of Hematology - Year 2011, Vol 28, Issue 2
Abstract
Objective: Despite the efficacy of the BCR-ABL tyrosine kinase inhibitor imatinib, the development of resistance against imatinib has been observed. The most important mechanisms known to cause resistance are point mutations in the ABL tyrosine kinase and the ATP domain. This study describes the use of denaturing high performance liquid chromatography (dHPLC) as a method to screen for mutations of the ABL gene. Material and Methods: We used the dHPLC based assay for the screening of ABL point mutations. Forty chronic myeloid leukemia (CML) patients who showed resistance to imatinib were screened in parallel by dHPLC and direct sequencing. Results: Nine of the 40 patients (23%) had mutations. Conclusion: dHPLC can be a useful method for pre-screening. Analyzing the mutations and monitoring (high-risk) patients can improve their prognosis and survival rate. dHPLC can potentially become a valuable tool for regular testing of patients in the future.
Authors and Affiliations
Yücel Erbilgin, Suzin Çatal, Ahmet Eşkazan, Özden Hatırnaz, Teoman Soysal, Uğur Özbek
Keywords
Related Articles
- EP ID EP85523
- DOI -
- Views 105
- Downloads 0
Severe Iron Deficiency Anemia due to late Presentation of Congenital Diaphragmatic Hernia in a Toddler
To the Editor, A 3-year-old female toddler was referred to our pediatric emergency unit with a 2-week history of fatigue, anorexia, progressive pallor, and vomiting. Medical history showed that iron deficiency anemia wa...
The Impact of DNMT3A/FLT3-ITD/NPM1 on Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
.
Outcome of Thrombotic Thrombocytopenic Purpura Patients: A Single-Center Experience
.
Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
Objective: High-doses of melphalan treatment with autologous stem cell transplantation in multiple myeloma (MM) remains a major treatment modality in suitable patients. A minimal dose of 2x106/kg CD34+ cells is preferred...
A Search for Beta Thalassemia Trait in India
To the Editor, The beta-thalassemia trait (BTT)—or beta-thalassemia minor—is a heterozygous condition in which only a single beta-globin gene is affected. The estimated prevalence of BTT in different regions of India is...